|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-10-08 |
Self-controlled, Single-site Trial Investigation of Laser Assisted Drug Delivery of NanoDOX®
This is a self-controlled single-site study of 10 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do two visits of approximately 4 hours over two weeks.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510 and NTC-510A) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.
To evaluate the efficacy of a single dose NTC-510 or NTC-510A for dental pain following third molar extraction.
Double-Blind, Single-Site, Pilot Study of NanoDOX Hydrogel Versus Placebo Hydrogel for Dehisced Surgical Wounds.
The purpose of this study is to determine the effects of NanoDOX Hydrogel versus Placebo Hydrogel on Dehisced Surgical Wounds.
100 项与 Nanoshift LLC 相关的临床结果
0 项与 Nanoshift LLC 相关的专利(医药)
100 项与 Nanoshift LLC 相关的药物交易
100 项与 Nanoshift LLC 相关的转化医学